We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: tuberculosis
MedXY News
EnglishTag

tuberculosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort
Infectious Diseasestranscriptomicstuberculosis

Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort

By MedXY|Sep 17, 2026

Host blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.

Congenital Tuberculosis in a 2-Week-Old Neonate With an Asymptomatic Mother
Infectious Diseasestuberculosis
neonatal infectious disease

Congenital Tuberculosis in a 2-Week-Old Neonate With an Asymptomatic Mother

By MedXY|Aug 20, 2026

A 2-week-old neonate developed congenital tuberculosis despite an asymptomatic mother, illustrating diagnostic challenges and the need for heightened awareness of TB in pregnancy.

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates
Clinical UpdatesAllo-HSCTepidemiology

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates

By MedXY|Apr 2, 2026

This review analyzes a decade-long nationwide study on TB after Allo-HSCT in France, revealing a 60/100,000 incidence rate, high extrapulmonary involvement, and the critical need for screening patients from high-incidence regions.

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
Clinical UpdatesAllo-HSCTinfectious disease

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

By MedXY|Mar 18, 2026

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for target

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
Infectious Diseasesinfectious diseasestuberculosis

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial

By MedXY|Jan 13, 2026

The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, an

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Infectious Diseasesclinical trialstuberculosis

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

By MedXY|Jan 13, 2026

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial
AIclinical trialmHealth

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial

By MedXY|Dec 24, 2025

An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
Infectious Diseasesclinical trialtuberculosis

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

By MedXY|Nov 24, 2025

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even

Unmasking the Silent Spread: Screening Asymptomatic Tuberculosis in Household Contacts in South Africa
Infectious Diseaseshousehold contactstuberculosis

Unmasking the Silent Spread: Screening Asymptomatic Tuberculosis in Household Contacts in South Africa

By MedXY|Oct 22, 2025

This study reveals that over 80% of tuberculosis cases among South African household contacts are asymptomatic and often missed by symptom and chest X-ray screening, highlighting the need for improved diagnostic strategies to detect subclin

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial
Clinical Updatesdose optimizationPharmacokinetics

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY|Oct 8, 2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings
Clinical UpdatesHIVimmunogenicity

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY|Oct 1, 2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities